Clinical trials: Monoclonal Gammopathy of Renal Significance (MGRS)
Monoclonal Gammopathy of Renal Significance
Diagnosis of MGRS in Patients With Paraproteinemias: Clinical, Anatomopathological and Pathophysiological Study
This is the first prospective study which evaluate patients with small B-cell clones to diagnose monoclonal gammopathy of renal significance (MGRS) and characterize it clinically, anatomopathologically and pathophysiologically…
- Trial name
- MGRS-CAPS (NCT03629561)
- Where
- Argentina
- Volunteers
- 15 people
- Sponsor
- Academia Nacional de Medicina
Kidney Failure, Paraproteinemias
The Effect of Daratumumab in Patients With Monoclonal Gammopathy of Renal Significance (MGRS) in Finland
The goal of this clinical trial is to learn if drug daratumumab works to treat kidney diseases other than AL-amyloidosis that fall under the category of monoclonal gammopathy of renal significance (MGRS).
- Conditions
- Kidney Failure, Paraproteinemias, Glomerulonephritis
- Trial name
- DAMOCLES (NCT06889948)
- Testing
- Daratumumab
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- Helsinki University Central Hospital
Monoclonal Gammopathy of Renal Significance
MGRS: Clinical-histological Features of a Multicenter Case Series
The term "Monoclonal Gammopathies of Renal Significance" (MGRS) describes a group of diseases characterized by the presence of an immunoglobulin or monoclonal immunoglobulin fraction that has the ability to cause renal damage.
- Trial name
- NCT05119309
- Where
- 8 sites in Italy
- Volunteers
- 87 people
- Sponsor
- University of Milano Bicocca
Multiple Myeloma, Monoclonal Gammopathy of Renal Significance
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated…
- Trial name
- NCT06083922
- Testing
- Cyclophosphamide, Bortezomib, Dexamethasone
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma, Amyloidosis
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study.
- Conditions
- Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease
- Trial name
- NCT05283993
- Testing
- No intervention
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Monoclonal Gammopathy of Renal Significance (MGRS)
Dara-BCD for Rare MGRS
This is an open-label, multicenter, phase 2 study in subjects with newly diagnosed proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMIDs), OR light chain proximal tubulopathy (LCPT), OR thrombotic…
- Trial name
- NCT06771180
- Testing
- Dara-CyBorD
- Volunteers
- 10 people
- Sponsor
- Peking University People's Hospital